146 related articles for article (PubMed ID: 36108672)
21. Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009-2014.
Shim SH; Kim H; Sohn IS; Hwang HS; Kwon HS; Lee SJ; Lee JY; Kim SN; Lee K; Chang S
J Gynecol Oncol; 2017 Sep; 28(5):e63. PubMed ID: 28657224
[TBL] [Abstract][Full Text] [Related]
22. Cervical cancer risk levels in Turkey and compliance to the national cervical cancer screening standard.
Açikgöz A; Ergör G
Asian Pac J Cancer Prev; 2011; 12(4):923-7. PubMed ID: 21790227
[TBL] [Abstract][Full Text] [Related]
23. Effect of gastric cancer screening on long-term survival of gastric cancer patients: results of Korean national cancer screening program.
Luu XQ; Lee K; Jun JK; Suh M; Jung KW; Choi KS
J Gastroenterol; 2022 Jul; 57(7):464-475. PubMed ID: 35568752
[TBL] [Abstract][Full Text] [Related]
24. Low Papanicolaou smear screening rate of women with HIV infection: a nationwide population-based study in Taiwan, 2000-2010.
Chen YC; Liu HY; Li CY; Lee NY; Ko WC; Chou CY; Hsieh TH; Ko NY
J Womens Health (Larchmt); 2013 Dec; 22(12):1016-22. PubMed ID: 23992102
[TBL] [Abstract][Full Text] [Related]
25. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
[No Abstract] [Full Text] [Related]
26. [Attendance rate in the Polish Cervical Cancer Screening Program in the years 2007-2009].
Spaczyński M; Karowicz-Bilinska A; Rokita W; Molińska-Glura M; Januszek-Michalecka L; Seroczyński P; Uchlik J; Nowak-Markwitz E
Ginekol Pol; 2010 Sep; 81(9):655-63. PubMed ID: 20973201
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with the intention to undergo Pap smear testing in the rural areas of Indonesia: a health belief model.
Sumarmi S; Hsu YY; Cheng YM; Lee SH
Reprod Health; 2021 Jun; 18(1):138. PubMed ID: 34193195
[TBL] [Abstract][Full Text] [Related]
28. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand.
Deerasamee S; Srivatanakul P; Sriplung H; Nilvachararung S; Tansuwan U; Pitakpraiwan P; Kaewkungwal J; Singhasivanon P; Nimnakorn P; Sankaranarayanan R
Asian Pac J Cancer Prev; 2007; 8(4):547-56. PubMed ID: 18260727
[TBL] [Abstract][Full Text] [Related]
29. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
[TBL] [Abstract][Full Text] [Related]
30. Sociodemographic factors of Pap smear screening in Taiwan.
Wang PD; Lin RS
Public Health; 1996 Mar; 110(2):123-7. PubMed ID: 8901257
[TBL] [Abstract][Full Text] [Related]
31. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program.
Nygård JF; Nygård M; Skare GB; Thoresen SØ
Cancer Causes Control; 2005 May; 16(4):463-74. PubMed ID: 15953989
[TBL] [Abstract][Full Text] [Related]
32. The frequency of Pap smear screening in the United States.
Sirovich BE; Welch HG
J Gen Intern Med; 2004 Mar; 19(3):243-50. PubMed ID: 15009779
[TBL] [Abstract][Full Text] [Related]
33. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras.
Perkins RB; Langrish SM; Stern LJ; Burgess JF; Simon CJ
Womens Health Issues; 2010; 20(1):35-42. PubMed ID: 19944623
[TBL] [Abstract][Full Text] [Related]
34. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
35. CIN 2/3 and cervical cancer after an ASCUS pap smear. A 7-year, prospective study of the Norwegian population-based, coordinated screening program.
Nygård JF; Sauer T; Skjeldestad FE; Skare GB; Thoresen SØ
Acta Cytol; 2003; 47(6):991-1000. PubMed ID: 14674068
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of cervical cancer screening strategies based on the Papanicolaou smear test in Korea.
Ko MJ; Kim J; Kim Y; Lee YJ; Hong SR; Lee JK
Asian Pac J Cancer Prev; 2015; 16(6):2317-22. PubMed ID: 25824757
[TBL] [Abstract][Full Text] [Related]
37. Cervical cancer screening: who is not screened and why?
Harlan LC; Bernstein AB; Kessler LG
Am J Public Health; 1991 Jul; 81(7):885-90. PubMed ID: 2053665
[TBL] [Abstract][Full Text] [Related]
38. Compliance with Papanicolaou smear screening following tubal ligation in women with cervical cancer.
Winkler HA; Anderson PS; Fields AL; Runowicz CD; DeVictoria C; Goldberg GL
J Womens Health; 1999; 8(1):103-7. PubMed ID: 10094087
[TBL] [Abstract][Full Text] [Related]
39. Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia.
Veerus P; Arbyn M; Amati C; Paolo B;
Tumori; 2010; 96(4):524-8. PubMed ID: 20968130
[TBL] [Abstract][Full Text] [Related]
40. Predictors of regular Pap smears among Korean-American women.
Juon HS; Seung-Lee C; Klassen AC
Prev Med; 2003 Dec; 37(6 Pt 1):585-92. PubMed ID: 14636792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
